Purpose We reported that nontoxic suramin treatments enhance the activity of chemotherapy
in preclinical models, a finding supported by the results of subsequent phase I/II trials in …

Human non-small cell lung cancer (N-SCLC), a common malignancy generally
unmanageable by conventional cytotoxic chemotherapy, represents a major world health …

AU‐rich elements (ARE) exist in the 3′‐untranslated regions of the mRNA transcribed from
cell growth‐related genes such as proto‐oncogenes, cyclin‐related genes, and growth …

Abstract Suramin-resistant DC-3F/SU 1000 Chinese hamster fibrosarcoma cells were
obtained by continuous exposure of parental DC-3F cells to increasing concentrations of …

Purpose In preclinical models, non-cytotoxic suramin (concentrations< 50 μM) potentiates
the activity of multiple chemotherapeutic agents. The present study evaluated the safety and …

Suramin is a polyanionic compound recently noted to inhibit growth factor action and
proliferation of several types of neoplastic cells in vitro. Data from clinical trials show …

Suramin is the first putative growth factor inhibitor in clinical trial that has demonstrated
antitumor activity. Bivariate flow cytometric analysis of the effects of suramin on the cell cycle …

The epidermal growth factor (EGF) is a potent growth factor that is believed to enhance the
proliferation of cancer cells by a paracrine or autocrine mechanism. EGF transduces various …

A sarcomatoid renal cell carcinoma has been isolated from a patient with Stauffer's
syndrome. The tumor, designated BA1119, has been established in tissue culture over 80 …

Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent
against selected tumours, and α2A-interferon (α2A-IFN) were investigated for their combined …